NCT04806503 - A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia. | Biotech Hunter

Enrollment

234

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

July 27, 2022

Study Completion Date

October 14, 2022

Conditions

Presbyopia

Interventions

DRUG

UNR844

Ophthalmic solution for topical ocular administration

DRUG

Placebo

Trial Locations (20)

2052

Novartis Investigative Site, Sydney

3002

Novartis Investigative Site, East Melbourne

18704

Novartis Investigative Site, Kingston

33773

Novartis Investigative Site, Largo

37167

Novartis Investigative Site, Smyrna

38119

Novartis Investigative Site, Memphis

57108

Novartis Investigative Site, Sioux Falls

60046

Novartis Investigative Site, Lake Villa

63090

Novartis Investigative Site, Washington

66762

Novartis Investigative Site, Pittsburg

78229

Novartis Investigative Site, San Antonio

92653

Novartis Investigative Site, Laguna Hills

92660

Novartis Investigative Site, Newport Beach

92663

Novartis Investigative Site, Newport Beach

V6H 1H6

Novartis Investigative Site, Vancouver

N2A 0K5

Novartis Investigative Site, Kitchener

N2L3G1

Novartis Investigative Site, Waterloo

G1S 4L8

Novartis Investigative Site, Québec

565-0853

Novartis Investigative Site, Suita

160-0008

Novartis Investigative Site, Shinjuku Ku